The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.

[1]  S. Krebs,et al.  Melanocyte antigen triggers autoimmunity in human psoriasis , 2015, The Journal of experimental medicine.

[2]  Dong Joo Kim,et al.  Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes, but Different Regulatory Gene Sets , 2015, The Journal of investigative dermatology.

[3]  P. Nikamo,et al.  Association with Genetic Variants in the IL-23 and NF-κB Pathways Discriminates between Mild and Severe Psoriasis Skin Disease. , 2015, The Journal of investigative dermatology.

[4]  J. Haeggström,et al.  Circulating levels of sphingosine-1-phosphate are elevated in severe, but not mild psoriasis and are unresponsive to anti-TNF-α treatment , 2015, Scientific Reports.

[5]  L. Ferris,et al.  Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. , 2015, The Journal of allergy and clinical immunology.

[6]  M. Suárez-Fariñas,et al.  Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions , 2015, F1000Research.

[7]  B. Marinari,et al.  The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis , 2014, Nature Communications.

[8]  C. Gabay,et al.  Inflammation: IL-36 has proinflammatory effects in skin but not in joints , 2014, Nature Reviews Rheumatology.

[9]  M. Schiattarella,et al.  Effects of adalimumab therapy in adult subjects with moderate‐to‐severe psoriasis on Th17 pathway , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  M. Suárez-Fariñas,et al.  IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model , 2014, PloS one.

[11]  G. Chodorowska,et al.  Serum Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients , 2013, Disease markers.

[12]  M. Lebwohl,et al.  Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. , 2013, JAMA dermatology.

[13]  T. McCormick,et al.  Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset. , 2013, Clinical immunology.

[14]  David A. Martin,et al.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. , 2013, Trends in immunology.

[15]  P. Muranski,et al.  Essentials of Th17 cell commitment and plasticity. , 2013, Blood.

[16]  H. Tian,et al.  Expression of Tumor Necrosis Factor Alpha-Induced Protein 3 mRNA in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Psoriasis Vulgaris , 2012, Clinical and Vaccine Immunology.

[17]  K. Ahn,et al.  A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis , 2012, The British journal of dermatology.

[18]  Suyan Tian,et al.  Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.

[19]  Mayte Suárez-Fariñas,et al.  Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.

[20]  A. Katsambas,et al.  The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept , 2011, Clinical and experimental dermatology.

[21]  David J. Margolis,et al.  Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom , 2011, The Journal of investigative dermatology.

[22]  T. McCormick,et al.  The dark side of regulatory T cells in psoriasis. , 2011, The Journal of investigative dermatology.

[23]  Scott B. Dewell,et al.  Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes , 2011, The Journal of investigative dermatology.

[24]  S. Sano,et al.  Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients , 2011, Archives of Dermatological Research.

[25]  W. Boehncke,et al.  The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.

[26]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[27]  P. Lipsky,et al.  Analysis of the Transcriptional Program of Developing Induced Regulatory T Cells , 2011, PloS one.

[28]  A. Morita,et al.  Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. , 2010, Journal of dermatological science.

[29]  Mayte Suárez-Fariñas,et al.  Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA) , 2010, PloS one.

[30]  C. Loddenkemper,et al.  Pronounced Phenotype in Activated Regulatory T Cells during a Chronic Helminth Infection , 2009, The Journal of Immunology.

[31]  Xing Li,et al.  Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. , 2009, The Journal of investigative dermatology.

[32]  A. Ishida-Yamamoto,et al.  Serum cytokines and growth factor levels in Japanese patients with psoriasis , 2009, Clinical and experimental dermatology.

[33]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[34]  Doheon Lee,et al.  Inferring Pathway Activity toward Precise Disease Classification , 2008, PLoS Comput. Biol..

[35]  Zhu Shen,et al.  Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris. , 2008, Journal of dermatological science.

[36]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[37]  J. Meyerovitch,et al.  Association between Psoriasis and the Metabolic Syndrome , 2008, Dermatology.

[38]  H. Dinh,et al.  Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation , 2007, The Journal of experimental medicine.

[39]  Khusru Asadullah,et al.  Immunopathogenesis of psoriasis , 2007, Experimental dermatology.

[40]  S. Gabriel,et al.  Heart disease in psoriasis. , 2007, Journal of the American Academy of Dermatology.

[41]  S. Piaserico,et al.  Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.

[42]  J. Heward,et al.  FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity , 2007, Nature Genetics.

[43]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2022, Central European journal of public health.

[44]  D. Margolis,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[45]  Jochen Schmitt,et al.  The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis , 2005, Dermatology.

[46]  D. Gladman,et al.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome , 2005, Annals of the rheumatic diseases.

[47]  C. Griffiths,et al.  Psoriasis: epidemiology, clinical features, and quality of life , 2005, Annals of the rheumatic diseases.

[48]  S. Stevens,et al.  Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation1 , 2005, The Journal of Immunology.

[49]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[50]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[51]  S. Feldman.  A quantitative definition of severe psoriasis for use in clinical trials , 2004, The Journal of dermatological treatment.

[52]  A. Bowcock,et al.  Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. , 2001, Human molecular genetics.

[53]  James T. Elder,et al.  Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? , 2000, Journal of the American Academy of Dermatology.

[54]  H. Iizuka,et al.  Calmodulin activities are significantly increased in both uninvolved and involved epidermis in psoriasis. , 1985, The Journal of investigative dermatology.

[55]  F. Kerdel,et al.  Short Communication Mediators of Inflammation, 12(5), 309 /313 (October 2003) BACKGROUND: Psoriatic plaques have been shown to , 2022 .